Time to maximum effect of lansoprazole on gastric pH in normal male volunteers

被引:39
作者
Bell, NJV [1 ]
Hunt, RH [1 ]
机构
[1] MCMASTER UNIV,MED CTR,DEPT MED,DIV GASTROENTEROL,HAMILTON,ON L8N 3Z5,CANADA
关键词
D O I
10.1046/j.1365-2036.1996.103242000.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The time to maximum inhibition of gastric acidity resulting from repeated oral dosing with lansoprazole 30 mg daily for 7 days was studied in nine healthy male volunteers. Methods: Twenty-four hour intragastric pH monitoring was performed before treatment and on days 1, 3, 5 and 7 of dosing with lansoprazole, Blood samples were taken for the estimation of plasma lansoprazole concentrations, Results: Lansoprazole 30 mg increased mean 24-h intragastric pH to 3.57 on day 1 compared with baseline mean pH of 2.11 (P < 0.05), The mean intragastric pH during the morning period (08.00-13.00 h) was significantly higher on days 3, 5 and 7 than on day 1, but no consistent differences between day 1, 3, 5 and 7 were noted for subsequent periods (13.00-18.00, 18.00-21.00 and 23.00-07.00 h), There were no differences in mean pH between days 3, 5 and 7, Intragastric pH was maintained above pH 3 for 54.7, 60.1, 61.9 and 67.4% of the time on days 1, 3, 5 and 7, respectively. Lansoprazole pharmacokinetic parameters did not change with daily dosing, The area under the lansoprazole plasma concentration-time curve correlated with the intragastric pH (P < 0.005). Conclusions: Lansoprazole 30 mg raised intragastric pH significantly from baseline on day 1 to a maximum effect as early as 6 h after the first dose, The degree and duration of acid suppression confirm the usefulness of lansoprazole for the treatment of acid-related disorders.
引用
收藏
页码:897 / 904
页数:8
相关论文
共 26 条
[1]  
AARONSON R, 1991, AM J GASTROENTEROL, V86, pA1307
[2]   PHARMACOKINETICS AND BIOAVAILABILITY OF OMEPRAZOLE AFTER SINGLE AND REPEATED ORAL-ADMINISTRATION IN HEALTHY-SUBJECTS [J].
ANDERSSON, T ;
ANDREN, K ;
CEDERBERG, C ;
LAGERSTROM, PO ;
LUNDBORG, P ;
SKANBERG, I .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (05) :557-563
[3]   APPROPRIATE ACID SUPPRESSION FOR THE MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE [J].
BELL, NJV ;
BURGET, D ;
HOWDEN, CW ;
WILKINSON, J ;
HUNT, RH .
DIGESTION, 1992, 51 :59-67
[4]   IS THERE AN OPTIMAL DEGREE OF ACID SUPPRESSION FOR HEALING OF DUODENAL-ULCERS - A MODEL OF THE RELATIONSHIP BETWEEN ULCER HEALING AND ACID SUPPRESSION [J].
BURGET, DW ;
CHIVERTON, SG ;
HUNT, RH .
GASTROENTEROLOGY, 1990, 99 (02) :345-351
[5]  
COLINJONES DG, 1993, ALIMENT PHARM THERAP, V7, P56
[6]  
DELHOTALLANDES B, 1993, EUR J CLIN PHARMACOL, V45, P367
[7]  
EKSTROM P, 1993, GASTROENTEROLOGY, V104, pA74
[8]   LANSOPRAZOLE VERSUS OMEPRAZOLE IN SHORT-TERM TREATMENT OF REFLUX ESOPHAGITIS - RESULTS OF A SCANDINAVIAN MULTICENTER TRIAL [J].
HATLEBAKK, JG ;
BERSTAD, A ;
CARLING, L ;
SVEDBERG, LE ;
UNGE, P ;
EKSTROM, P ;
HALVORSEN, L ;
STALLEMO, A ;
HOVDENAK, N ;
TRONDSTAD, R ;
KITTANG, E ;
LANGE, OJ .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1993, 28 (03) :224-228
[9]  
HOTZ J, 1992, ALIMENT PHARM THERAP, V6, P87
[10]  
HOWDEN C W, 1991, Gastroenterology, V100, pA85